Attovia Therapeutics (NASDAQ:ATTO) Posts Earnings Results

Attovia Therapeutics (NASDAQ:ATTO) posted its quarterly earnings results on Wednesday. The company reported ($4.88) earnings per share for the quarter, Zacks reports.

Attovia Therapeutics Price Performance

ATTO opened at $23.13 on Thursday. Attovia Therapeutics has a 52 week low of $16.15 and a 52 week high of $24.32.

Attovia Therapeutics News Roundup

Here are the key news stories impacting Attovia Therapeutics this week:

• Positive Sentiment: Positive ATTO-1310 clinical update: Attovia reported preliminary proof of concept for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis. Complete Phase 1b data are expected in the fourth quarter of 2026, providing a near-term catalyst. Attovia Therapeutics second-quarter results and corporate update
• Positive Sentiment: New bullish analyst coverage: LifeSci Capital initiated coverage with an “outperform” recommendation. Citigroup, Leerink Partners and Royal Bank of Canada also began coverage, increasing institutional visibility around the biotech. LifeSci Capital coverage
• Positive Sentiment: Royal Bank of Canada recently upgraded Attovia to “moderate buy,” reinforcing the positive analyst sentiment surrounding the company’s pipeline. Royal Bank of Canada upgrade
• Neutral Sentiment: Attovia’s second-quarter earnings release provides investors with an updated financial and corporate overview, with attention likely focused on development spending and the company’s ability to fund upcoming clinical work. Attovia Therapeutics earnings press release
• Negative Sentiment: Widening quarterly loss: Attovia reported a second-quarter loss of $4.88 per share, while separate coverage characterized the company’s net loss as wider than in the prior-year period. Continued losses could weigh on the stock if investors become concerned about cash needs or execution risk. Attovia Therapeutics Q2 net loss

Analyst Ratings Changes

A number of analysts recently commented on the stock. Lifesci Capital assumed coverage on shares of Attovia Therapeutics in a report on Monday. They set an “outperform” rating and a $45.00 price objective on the stock. Royal Bank Of Canada initiated coverage on Attovia Therapeutics in a report on Monday. They issued an “outperform” rating and a $45.00 price target on the stock. Citigroup started coverage on Attovia Therapeutics in a research note on Monday. They issued a “buy” rating and a $30.00 price objective for the company. Morgan Stanley began coverage on Attovia Therapeutics in a report on Monday. They set an “overweight” rating and a $39.00 price objective for the company. Finally, Leerink Partners began coverage on Attovia Therapeutics in a research report on Monday. They set an “outperform” rating and a $52.00 target price on the stock. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $42.20.

Insider Transactions at Attovia Therapeutics

In other news, Director Colin Walsh bought 500,000 shares of Attovia Therapeutics stock in a transaction on Thursday, August 6th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $8,500,000.00. Following the acquisition, the director owned 3,020,632 shares in the company, valued at approximately $51,350,744. This trade represents a 19.84% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Life Sciences Xi L.P. Frazier purchased 588,235 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $9,999,995.00. Following the completion of the purchase, the insider directly owned 6,154,213 shares in the company, valued at $104,621,621. The trade was a 10.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 2,740,587 shares of company stock worth $47,269,979 in the last ninety days. Company insiders own 0.99% of the company’s stock.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.